4β-Hydroxycholesterol Level in Patients With Rheumatoid Arthritis Before vs. After Initiation of bDMARDs and...

Area of Science:

• Pharmacology
• Immunology
• Rheumatology

Background:

• Systemic inflammation is known to suppress CYP3A4 enzyme activity.
• 4β-hydroxycholesterol (4βOHC) is an endogenous metabolite reflecting CYP3A4 activity.
• Rheumatoid arthritis (RA) is a systemic inflammatory disease.

Purpose of the Study:

• To determine if biological disease-modifying antirheumatic drugs (bDMARDs) restore CYP3A4 activity in RA patients.
• To assess changes in 4βOHC levels before and after bDMARD treatment.
• To investigate correlations between 4βOHC and inflammatory markers (CRP, ESR) during RA treatment.

Main Methods:

• Measured 4βOHC levels in 41 RA patients before and 2-5 months after initiating bDMARDs (TNFα, IL-6, or B-cell inhibitors).
• Assessed C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) as inflammatory markers.
• Correlated 4βOHC levels with CRP and ESR before and after bDMARD therapy.

Main Results:

• 4βOHC levels did not significantly change after bDMARD treatment (P=0.6).
• No significant difference in 4βOHC was observed in patients treated with IL-6 inhibitors.
• Significant correlations between 4βOHC and CRP (r=-0.40) and ESR (r=-0.34) emerged post-treatment, unlike pre-treatment.

Conclusions:

• Initiation of bDMARDs in RA patients does not generally restore CYP3A4 enzyme activity.
• Post-treatment correlations suggest reduction of non-CYP3A4-suppressive inflammatory cytokines.
• Further research is needed to understand drug metabolism changes in inflammatory conditions.